Related Experiment Videos
[Bezafibrate in primary hyperlipidemias (author's transl)]
Klinische Wochenschrift
|January 15, 1982
Summary
Bezafibrate treatment significantly lowered cholesterol and triglycerides while increasing HDL-cholesterol in patients with hyperlipoproteinemias. This study investigated the long-term effects of Bezafibrate on lipid profiles.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biochemistry
Context:
- Primary hyperlipoproteinemias (HLP) are genetic disorders affecting lipid metabolism.
- Effective management of HLP is crucial for reducing cardiovascular disease risk.
- Bezafibrate is a fibrate drug known for its lipid-lowering properties.
Purpose:
- To evaluate the long-term efficacy of Bezafibrate in treating various types of primary hyperlipoproteinemias.
- To assess the impact of Bezafibrate on total cholesterol, HDL-cholesterol, and triglycerides.
- To investigate the effect of Bezafibrate on postheparin-lipoprotein-lipase (PHLA) activity.
Summary:
- Long-term Bezafibrate treatment (40 weeks) in 27 HLP patients (types IIa, IIb, III, IV, V) resulted in a 16% reduction in total cholesterol.
- Serum triglycerides decreased significantly by 59-66% with Bezafibrate, and HDL-cholesterol increased by 28-36%.
- Bezafibrate activated PHLA by 30% and was associated with few side effects.
Impact:
- Bezafibrate demonstrates significant lipid-modifying effects across different hyperlipoproteinemia types.
- The drug's ability to increase HDL-cholesterol and decrease triglycerides suggests a potential benefit in cardiovascular risk reduction.
- Further research could explore Bezafibrate's role in personalized HLP management and its long-term cardiovascular outcomes.